Research Technologies Branch
Established in 2000
James M. Cherry, Ph.D.
Associate Director, Research Technologies, DIR, NIAID
Chief, Research Technology Branch
Contracting Officer Representative (COR III), FFRDC, RTB, DIR, NIAID
Project/Program Manager (FAC-P/PM II) FFRDC, RTB, DIR, NIAID
Contact: For contact information, search the NIH Enterprise Directory.

Major Areas of Research
- Monitors new developments in the biotechnology industry
- Translates new technology applications into useful applications for biomedical research
- Develop project-specific applications using state-of-the-art technologies
- Technology Transfer and consultation
- Offer formal and informal training, support, and troubleshooting
- Evaluate new technologies applications
- Established a new bioinformatics application that fully support investigators computational scientific needs
Program Description
The Research Technologies Branch (RTB) provides cutting edge expertise and research technologies primarily in support of NIAID intramural investigators. Our Lab was established to provide researchers access to leading-edge technologies and specialized expertise through a tightly integrated, highly effective approach to study complex biological problems. During the past 30 years, the advent of the biotechnology industry and the development of new scientific disciplines have resulted in an explosion of new technologies. In addition, advances in optics, lasers, and computational biology have revolutionized well-established disciplines such as microscopy (light and electron), flow cytometry, genomic and proteomics. These technologies require very expensive instrumentation platform integration and more importantly highly trained specialized scientists to adapt these new technologies to the research needs of the Institute’s diverse research agenda. The Branch implements state of the art research technologies and project-specific applications for the NIAID intramural research program. This is accomplished through collaboration with current researchers along with a network of facilities located in Bethesda, Rockville and Frederick, Maryland, as well as Hamilton, Montana. Scientists in the RTB make significant contributions to collaborative research projects with NIAID researchers and their extramural collaborators. Equally important is their dedication technology; a substantial portion of their efforts focuses on technology development, resulting in advances methods and approaches designed.
The Center for Human Immunology (CHI) mission is to achieve an integrated and predictive understanding of human immunity and immune-microbiome behavior and function in health and disease. This can be accomplished by large scale human studies, scientific expertise and a strong influx of technology applications that is not readily available in a single laboratory.
Biography
Education
Ph.D., Catholic University of America
M.S., Johns Hopkins University
B.S., Shepherd University
Dr. Jim Cherry obtained his Ph.D. from the Catholic University of America in molecular biology with a concentration in bio-medical science. He earned an M.S. from Johns Hopkins University in molecular biology with a concentration in biotechnology. His bachelors degree is from Shepherd University with a major in biology and minor in chemistry.
Selected Publications
Pinto LA, Shawar RM, O'Leary B, Kemp TJ, Cherry J, Thornburg N, Miller CN, Gallagher PS, Stenzel T, Schuck B, Owen SM, Kondratovich M, Satheshkumar PS, Schuh A, Lester S, Cassetti MC, Sharpless NE, Gitterman S, Lowy DR. A Trans-Governmental Collaboration to Independently Evaluate SARS-CoV-2 Serology Assays. Microbiol Spectr. 2022 Feb 23;10(1):e0156421.
Rozenblum E, Sotelo-Silveira JR, Kim GY, Zhu JY, Lau CC, McNeil N, Korolevich S, Liao H, Cherry JM, Munroe DJ, Ried T, Meltzer PS, Kuehl WM, Roschke AV. Novel near-diploid ovarian cancer cell line derived from a highly aneuploid metastatic ovarian tumor. PLoS One. 2017 Aug 7;12(8):e0182610.
Cabarcas SM, Thomas S, Zhang X, Cherry JM, Sebastian T, Yerramilli S, Lader E, Farrar WL, Hurt EM. The role of upregulated miRNAs and the identification of novel mRNA targets in prostatospheres. Genomics. 2012 Feb;99(2):108-17.
Urzúa U, Owens GA, Zhang GM, Cherry JM, Sharp JJ, Munroe DJ. Tumor and reproductive traits are linked by RNA metabolism genes in the mouse ovary: a transcriptome-phenotype association analysis. BMC Genomics. 2010 Dec 22;11 Suppl 5(Suppl 5):S1.
Roth MJ, Wei WQ, Baer J, Abnet CC, Wang GQ, Sternberg LR, Warner AC, Johnson LL, Lu N, Giffen CA, Dawsey SM, Qiao YL, Cherry J. Aryl hydrocarbon receptor expression is associated with a family history of upper gastrointestinal tract cancer in a high-risk population exposed to aromatic hydrocarbons. Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2391-6.
Althoff KN, Schlueter DJ, Anton-Culver H, Cherry J, Denny JC, Thomsen I, Karlson EW, Havers FP, Cicek MS, Thibodeau SN, Pinto LA, Lowy D, Malin BA, Ohno-Machado L, Williams C, Goldstein D, Kouame A, Ramirez A, Roman A, Sharpless NE, Gebo KA, Schully SD. Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020. Clin Infect Dis. 2022 Mar 1;74(4):584-590.